Herceptin, Enbrel Face First Biosimilar Rivals In Japan But Outlook Uncertain

The first biosimilar versions in Japan of two major biologic therapies, Herceptin and Enbrel, have been awarded reimbursement prices, clearing the way for launch, but commercial prospects remain uncertain.